INTRODUCTION: The risk of ipsilateral breast tumour recurrence (IBTR) following breast conservation surgery (BCS) for invasive breast cancer (IBC) and radiotherapy is dependent on patient-, tumour- and treatment-related variables. In the Cambridge Breast Unit, breast conserving surgery has been performed with a target radial margin of 5 mm for IBC, in combination with 40-Gy hypofractionated (15 fractions) breast radiotherapy, since 1999. PATIENTS AND METHODS: An audit was performed of cases treated between 1999 and 2004. A total of 563 patients underwent BCS for invasive breast cancer with 90.4% receiving radiotherapy (RT) and 60.4% of patients receiving boost RT (3 fractions of 3-Gy). RESULTS: After a median follow-up of 58 months, five of the 563 (0.9%) patients developed IBTR. The 5-year actuarial IBTR rate was 1.1%. In terms of distant disease recurrence (DDR), 29 of the 563 (5.2%) had DDR during follow-up, giving a 5-year actuarial DDR rate of 5.4%. The 5-year breast cancer specific survival was 95%, with the poorer NPI groups having worse breast cancer specific survival (Log-rank, P<0.0001). More importantly, patients with IBTR had a shorter breast cancer-specific survival than those who were IBTR-free (Log-rank, P<0.0001). CONCLUSIONS: Our treatment regimen, combining BCS with a 5-mm target margin and hypofractionated 40-Gy RT, results in an extremely low rate of IBTR, and compares favourably with the target IBTR rate of <5% defined by the Association of Breast Surgeons (ABS) at BASO guidelines.
INTRODUCTION: The risk of ipsilateral breast tumour recurrence (IBTR) following breast conservation surgery (BCS) for invasive breast cancer (IBC) and radiotherapy is dependent on patient-, tumour- and treatment-related variables. In the Cambridge Breast Unit, breast conserving surgery has been performed with a target radial margin of 5 mm for IBC, in combination with 40-Gy hypofractionated (15 fractions) breast radiotherapy, since 1999. PATIENTS AND METHODS: An audit was performed of cases treated between 1999 and 2004. A total of 563 patients underwent BCS for invasive breast cancer with 90.4% receiving radiotherapy (RT) and 60.4% of patients receiving boost RT (3 fractions of 3-Gy). RESULTS: After a median follow-up of 58 months, five of the 563 (0.9%) patients developed IBTR. The 5-year actuarial IBTR rate was 1.1%. In terms of distant disease recurrence (DDR), 29 of the 563 (5.2%) had DDR during follow-up, giving a 5-year actuarial DDR rate of 5.4%. The 5-year breast cancer specific survival was 95%, with the poorer NPI groups having worse breast cancer specific survival (Log-rank, P<0.0001). More importantly, patients with IBTR had a shorter breast cancer-specific survival than those who were IBTR-free (Log-rank, P<0.0001). CONCLUSIONS: Our treatment regimen, combining BCS with a 5-mm target margin and hypofractionated 40-Gy RT, results in an extremely low rate of IBTR, and compares favourably with the target IBTR rate of <5% defined by the Association of Breast Surgeons (ABS) at BASO guidelines.
Authors: J Horiguchi; Y Iino; H Takei; M Maemura; T Yokoe; H Niibe; M Yamakawa; T Nakajima; T Oyama; Y Morishita Journal: Oncol Rep Date: 1999 Jan-Feb Impact factor: 3.906
Authors: B J Fisher; F E Perera; A L Cooke; A Opeitum; V Venkatesan; A R Dar; L Stitt Journal: Int J Radiat Oncol Biol Phys Date: 1997-06-01 Impact factor: 7.038
Authors: Nadeem Q Mirza; Georges Vlastos; Funda Meric; Thomas A Buchholz; Nestor Esnaola; S Eva Singletary; Henry M Kuerer; Lisa A Newman; Frederick C Ames; Merrick I Ross; Barry W Feig; Raphael E Pollock; Marsha McNeese; Eric Strom; Kelly K Hunt Journal: Ann Surg Oncol Date: 2002-04 Impact factor: 5.344
Authors: Wedad M. Hanna; Harriette J. Kahn; Judy-Anne W. Chapman; Edward B. Fish; H. Lavina A. Lickley; David R. McCready Journal: Breast J Date: 1999-03 Impact factor: 2.431
Authors: Dylan V Miller; Alexey A Leontovich; Wilma L Lingle; Vera J Suman; Maureen L Mertens; James Lillie; Kimberly A Ingalls; Edith A Perez; James N Ingle; Fergus J Couch; Daniel W Visscher Journal: Mod Pathol Date: 2004-07 Impact factor: 7.842
Authors: I Fredriksson; G Liljegren; M Palm-Sjövall; L-G Arnesson; S O Emdin; T Fornander; A Lindgren; H Nordgren; I Idvall; M Holmqvist; L Holmberg; J Frisell Journal: Br J Surg Date: 2003-09 Impact factor: 6.939
Authors: R Schmidt-Ullrich; D E Wazer; O Tercilla; H Safaii; D J Marchant; T J Smith; M A Homer; N J Robert Journal: Int J Radiat Oncol Biol Phys Date: 1989-10 Impact factor: 7.038
Authors: James Mansell; Ian J Monypenny; Anthony I Skene; Paul Abram; Robert Carpenter; Jennifer M Gattuso; Christopher R Wilson; Wilson J Angerson; Julie C Doughty Journal: Breast Cancer Res Treat Date: 2008-12-27 Impact factor: 4.872
Authors: R M Clark; P B McCulloch; M N Levine; M Lipa; R H Wilkinson; L J Mahoney; V R Basrur; B D Nair; R S McDermot; C S Wong Journal: J Natl Cancer Inst Date: 1992-05-06 Impact factor: 13.506
Authors: James R Bundred; Sarah Michael; Beth Stuart; Ramsey I Cutress; Kerri Beckmann; Bernd Holleczek; Jane E Dahlstrom; Jacqui Gath; David Dodwell; Nigel J Bundred Journal: BMJ Date: 2022-09-21